Sarepta Therapeutics (SRPT) Change in Receivables (2010 - 2026)

Sarepta Therapeutics' Change in Receivables history runs 17 years deep, the most recent figure standing at -$3.4 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 105.95% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at -$264.6 million (down 194.29% YoY), while the FY2025 annual figure was -$203.8 million, down 201.04% from the prior year.
• Change in Receivables was -$3.4 million for Q1 2026 at Sarepta Therapeutics, down from $2.5 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $167.5 million in Q4 2024 to a low of -$132.1 million in Q2 2025.
• Historically, Change in Receivables has averaged $14.2 million across 5 years, with a median of $13.0 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Change in Receivables jumped 3598.81% in 2023, then slumped 602.2% in 2025.
• A 5-year view of Change in Receivables shows it stood at $13.1 million in 2022, then surged by 521.02% to $81.5 million in 2023, then jumped by 105.55% to $167.5 million in 2024, then sank by 98.51% to $2.5 million in 2025, then sank by 236.97% to -$3.4 million in 2026.
• The last three Change in Receivables figures came in at -$3.4 million (Q1 2026), $2.5 million (Q4 2025), and -$131.6 million (Q3 2025), per Business Quant data.